Subjects
For the population genetics, the samples were convenience samples obtained from an anonymized collection of the Department of Human Genetics, Instituto Nacional de Saúde Doutor Ricardo Jorge, and included 200 Portuguese general population and 148 Central African individuals, for 57% (85/148) of which at least one of the parents was Angolan.
For genetic association studies with influenza severity, 41 Portuguese patients with laboratory confirmed influenza A(H1N1)pdm09 infection were selected and classified either as “mild cases” receiving ambulatory treatment only or as “severe cases” requiring admission to intensive care units (ICUs). Criteria for admission to ICUs included pneumonia or dyspnea. Chronic medical conditions, identified as potential A(H1N1)pdm09 risk factors (Van Kerkhove et al. 2011), in these patients included immunosuppression (cancer, HIV infection, Crohn’s disease, and organ transplant), diabetes, chronic respiratory conditions, e.g., asthma, and cardiovascular disease. For influenza laboratory diagnosis, viral nucleic acid extraction from oropharyngeal swabs was performed using the automated extractor EasyMag (bioMérieux, Lyon, France) according to the manufacturer’s recommendations. The presence of influenza virus was searched for by real-time RT-PCR, using a protocol kindly provided by the Health Protection Agency, UK. All the samples collected from the hospitalized and community patients and associated data were anonymized prior to investigation.
Genotyping
Human genomic DNA was extracted from peripheral leukocytes using MagNA Pure LC (Roche Diagnostics GmbH, Mannheim, Germany) and from nasopharyngeal swabs using the QIAamp® Viral RNA Mini Kit (Qiagen, Hilden, Germany). PCR amplification of the 352 bp fragment in the first exon of the IFITM3 gene (DNA position chr11: 320,556–320,907, GRCh38/hg38) was carried out using the forward and reverse primers: 5′-GGAAACTGTTGAGAAACCGAA-3′ and 5′- CATACGCACCTTCACGGAGT-3′ (Zhang et al. 2013). The PCR products were purified and sequenced with BigDye Terminator v1.1 Sequencing Standard Kit (Applied Biosystems, Portugal) and analyzed with the ABI 3130 XL Genetic Analyzer (Applied Biosystems, MA, USA). Sequences were analyzed using FinchLab™ (Geospiza). Haplotypes were reconstructed from the genotyping data using the PHASE, version 2.1, program (Stephens et al. 2001, Stephens and Donnelly 2003).
Association testing
Association of genetic variants to disease severity was assessed by IFITM3 genotyping of the individuals with severe influenza and those with mild influenza. The latter were considered to be a better control for the studies of association to severe influenza, rather than the general Portuguese population group, for which the status of influenza infection was unknown. However, the frequencies of the SNPs and haplotypes between each patients’ group and the general Portuguese population were also compared. Hardy-Weinberg equilibrium (HWE) calculations were performed in the general population and influenza patient groups. Only SNPs under HWE and with minor allele frequency > 5% in both case and control groups were analyzed for association.
Statistical analysis of genetic data was performed using R-stats library in the R-Statistical package, R Development Core Team (http://www.R-project.org). The chi-square test was used for testing association under different genetic models. As the chi-square assumptions did not always hold, due to small sample size, the Fisher’s Exact Probability Test (two-tailed) was also used. The odds ratio (OR) was calculated under different genetic models to measure the risk of severe influenza. To evaluate the possible confounding effects of age, gender, and chronic medical condition, the chi-square test was used to test for association of these factors to genotype as well as to mild and severe influenza. Estimates of the statistical powers for the effect size range of the chi-square test used in association testing in our patient population (n = 41) were obtained. The chi-square test was also used for analyzing the frequencies of the SNPs and haplotypes between each patients’ group and the general Portuguese population.
Results of the genotype-to-phenotype association testing were presented with the OR and confidence interval (CI) revealing the degree of precision in the size of the effect. In this study, the statistical significance must be interpreted with reserve due to the reduced sample size. Moreover, the expected size of the effect for common “low-penetrant” variants such as observed for SNP rs34481144 in the Portuguese population is small (Alcaïs et al. 2009), making it more difficult to detect. Therefore, we assumed, in the context of this preliminary study and in the light of the current interest in the exploration of the IFITM3 promoter variants for their effect on viral influenza clinical phenotypes in populations of different ancestries, that it was justifiable to also report the 10% significance levels, designated “borderline” as being suggestive but not conclusive. For these the 90% CI of the OR was also calculated. It can further be recalled that the choice of the significance level does not prove that the null hypothesis is either right or wrong (Beaglehole et al. 1993). Moreover, to increase stringency, the False Discovery Rate criterion (FDR) was performed for the genetic models tested per SNP and for all the haplotypes tested, although, given the non-random basis for the study of the IFITM3 genetic loci, correction for multiple testing would not be mandatory.
The population attributable risk (PAR), the fraction of the population risk of severe influenza outcome attributable to the studied allele or genotype, was estimated as follows: PAR% = 100 × p (1 − OR) / [p (1 − OR) + 1], where p is the prevalence of the studied allele in the general population(or mild influenza patient group) and OR represents an estimate of the relative risk of a severe infection outcome in the population with the studied allele (or genotype) compared to the population that does not carry the allele.
Gene expression
The biological significance of rs34481144, in altering gene expression levels, was tested in a HeLa cell system using a protocol adapted from Shen et al. (2013). For this a 347-bp region of the IFITM3 promoter was amplified, using the forward 5′-TATACTGCAGCTAGCGAGCCCTGAACCGGGACAGTG-3′ and reverse 5′-TATACTGCACTCGAGTGGTGTCCAGCGAAGACCAGC-3′ primers, and cloned into a pGL3 basic plasmid (Promega, Madison, WI, USA) between the NheI and XhoI restriction sites. Site-directed mutagenesis, of the c.-23G>A (rs34481144) site in the pGL3-IFITM3 construct, was carried out using the forward and reverse primers, 5′-CCAGTAACCCGACCACCGCTGGTCTTCGC-3′ and 5′-GCGAAGACCAGCGGTGGTCGGGTTACTGG-3′, respectively, in a reaction mix containing KOD Hot Start buffer (1×) (Novagen TOYOBO), KOD Hot Start polymerase (1 U), MgSO4 1.5 mM (Novagen TOYOBO), dNTPs 10 mM (Promega, Madison, WI, USA), primers (0.3 μM each) and 250 ng plasmid DNA. DNA was submitted to denaturation at 95 °C for 10 min, followed by 12 cycles at 95 °C for 1 min, 55 °C for 1 min and 68 °C for 16 min, and a final extension step at 68 °C for 10 min. After the mutagenesis reaction, the original templates were digested with the DpnI, 1.5 h at 37 °C. The mutation was confirmed by DNA sequencing.
For cell culture and luciferase assays, HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco BRL, USA) supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 U/ml). Twenty-four-hour cultured HeLa cells, seeded in 48-well plates, were transfected with the constructed pGL3-IFITM3 and the pGL4.70hCMV plasmids, using Lipofectamine 2000 (Invitrogen, USA) in GIBCO™ in Opti-MEM I Reduced-Serum Medium (Gibco BRL, USA). Assays were performed on cells treated at 20 h, or not, with human recombinant IFN-γ or IFN-α (Alpha 2a) (final concentration of 100 pg/ml and 100 ng/ml). Firefly luciferase and renilla luciferase (via pGL3-basic and pGL4.70hCMV, respectively) luminescences were sequentially measured using a Dual-Luciferase Reporter Assay System (Promega, USA). Results were expressed as the ratio of light units of firefly luciferase activity over light units of renilla luciferase activity. All experiments were performed in triplicate and repeated three times.